The Patent Finder

Immatics Biotechnologies GmbH

Also on record
Records under this name other than the patents Immatics Biotechnologies GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 476 patents it holds.

Back to Immatics Biotechnologies GmbH

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,513,547Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
In force
 · High confidence
In forceHigh confidence
US 12,312,412MAGEB2 Binding Constructs
In force
 · High confidence
In forceHigh confidence
US 7,807,642Tumor-Associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules
Term ended
Term ended Nov 17, 2026 · High confidence
Term endedTerm ended Nov 17, 2026High confidence
US 10,196,432Tumor-Associated Peptides Binding to Human Leukocyte Antigen (HLA) Class II Molecules
Term ended
Term ended Nov 17, 2026 · High confidence
Term endedTerm ended Nov 17, 2026High confidence
US 10,105,428Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers
Lapsed on the fee record
Ended Oct 23, 2026 · Low confidence
Lapsed on the fee recordEnded Oct 23, 2026Low confidence
US 10,106,593Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors
Lapsed on the fee record
Ended Oct 23, 2026 · Low confidence
Lapsed on the fee recordEnded Oct 23, 2026Low confidence
US 10,106,594Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors
Lapsed on the fee record
Ended Oct 23, 2026 · Low confidence
Lapsed on the fee recordEnded Oct 23, 2026Low confidence
US 7,811,828Method for Identifying and Quantifying of Tumour-Associated
Term ended
Term ended Oct 16, 2026 · Medium confidence
Term endedTerm ended Oct 16, 2026Medium confidence
US 10,098,937Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers
Lapsed on the fee record
Ended Oct 16, 2026 · Low confidence
Lapsed on the fee recordEnded Oct 16, 2026Low confidence
US 10,098,938Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers
Lapsed on the fee record
Ended Oct 16, 2026 · Low confidence
Lapsed on the fee recordEnded Oct 16, 2026Low confidence
10 of 551 records shown.
Pro members see all 551.
Pro members: see all 551 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited